Jul 16, 2018
Neurotrope Announces the Initiation of Enrollment of its Confirmatory Phase 2 Trial in Alzheimer's Disease
Jul 02, 2018
Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting
Jun 27, 2018
Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
May 17, 2018
Aptinyx Appoints Robert Hombach to Board of Directors
Apr 03, 2018
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
Mar 21, 2018
Aptinyx to Present at Needham & Company's 17th Annual Healthcare Conference
Mar 15, 2018
Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson's Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018
Mar 06, 2018
Aptinyx Presents NYX-2925 Preclinical Data in Chemotherapy-induced Neuropathic Pain at the American Pain Society Annual Scientific Meeting
Feb 13, 2018
Aptinyx Appoints Ashish Khanna Chief Financial Officer and Chief Business Officer
Jan 18, 2018
Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist
Jan 17, 2018
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
Jan 09, 2018
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
Dec 28, 2017
Aptinyx to Present at 36th Annual J.P. Morgan Healthcare Conference
Dec 22, 2017
Breakthrough Treatment IV Ketamine Infusions for CRPS, Fibromyalgia, Depression, PTSD, Chronic Lyme, Rheumatoid Arthritis and More Now Covered By Insurance!
Dec 18, 2017
Aptinyx Raises $70 Million in Series B Financing to Advance Growing Pipeline through Clinical Studies in Neurologic Disorders
Dec 07, 2017
Aptinyx Bolsters Executive Leadership Team with Appointment of Andy Kidd as Chief Commercial Officer
Dec 07, 2017
Aptinyx Granted Fast Track Designation, Initiates Phase 1 for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder
Nov 14, 2017
Aptinyx to Present Preclinical Data for NMDA Receptor Modulators in Neurologic Disorders at Neuroscience 2017
Oct 27, 2017
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
Oct 17, 2017
Cadent Therapeutics Receives Milestone for the Initiation of Phase 1 Clinical Studies